Giving hope to those affected
by secondary breast cancer

Research. Support. Education.
Donate M2C Shop Newsletter

UK Clinical Trial Registry

This registry lists all of the clinical trials that are currently actively recruiting secondary breast cancer patients in the UK.

Currently, patients and healthcare professionals have to search many different databases, such as clinicaltrials.gov, NIHR Be Part of Research or Cancer Research UK, to see what trials might be available. These databases use different search algorithms and the outcome of searches can be different and very time-consuming. This registry is intended as a “one stop shop” for UK secondary breast cancer clinical trials.

Clinical Trials for Secondary (Metastatic) Breast Cancer

The registry is divided into different categories based on the medical classification of secondary breast cancer. You can select a category to see a list of available trials and click on the study links to find the eligibility criteria. If you are unsure of your subtype, please speak to your clinical team. You can read more about the subtypes and receptors for breast cancer here. 

Next steps

If you are interested in trials, it is important to have a conversation with your clinical team and people around you who can support you. At Make 2nds Count, we offer an impartial and confidential Patient Trials Advocate (PTA) service for those interested in finding out more about clinical trials. Book an appointment with our friendly team of specialist nurses today.

Please see the Footnotes for Healthcare Professionals at the bottom of this page to learn how this registry is compiled and why it was developed. 

Jump to category:

ER+ or HR+ & HER2-

For patients who are oestrogen receptor positive, hormone receptor positive and HER2 (human epidermal growth factor receptor 2) negative.

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05194072

Recruiting now in:

  • London

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info: clinicaltrials.gov/ct2/show/NCT04796324

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info: clinicaltrials.gov/ct2/show/NCT03048942

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

D4 Choline Breast PET/CT: Investigation of Changes in Tumour Choline Metabolism in Estrogen-receptor Positive / HER2 Negative Breast Cancer Patients Treated With CDK4/6 Inhibitors and Endocrine Therapy

Observational imaging study

More info: clinicaltrials.gov/ct2/show/NCT04276272

Recruiting now in:

  • London

ELECTRA: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Phase 1b/2: Patients with brain metastases that are ER+ or HR+ & HER2- who have had at least one endocrine therapy, up to two chemotherapy regimens and up to two prior CDK 4/6 inhibitors, not including abemaciclib

More info: classic.clinicaltrials.gov/ct2/show/NCT05386108

Recruiting now in:

  • London
  • Manchester

evERA Breast Cancer: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Metastatic Breast Can

Phase 3, prior endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors.

More info: clinicaltrials.gov/ct2/show/NCT05306340

Recruiting now in:

  • Dorset
  • London
  • Manchester
  • Nottingham

FAIM: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Phase 2, HR+/HER2- metastatic breast cancer & previously treated with no more than one prior line of chemotherapy for advanced disease

More info: clinicaltrials.gov/study/NCT04920708

Recruiting now in:

  • Cambridge
  • Edinburgh
  • Glasgow
  • London
  • Manchester
  • Nottingham
  • Truro

INAVO120: A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Phase 2 & 3, HR+ & HER2- & PIK3CA-Mutant

More info: clinicaltrials.gov/ct2/show/NCT04191499

Recruiting now in:

  • Harlow
  • London
  • Maidstone
  • Plymouth
  • Sutton

INAVO121: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/​6i and En

Phase 3: Patients who are ER+ or HR+ & HER2- and have a PIK3CA mutation and have progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy

More info: clinicaltrials.gov/study/NCT05646862

Recruiting now in:

  • Basingstoke
  • Blackpool
  • Edinburgh
  • Harlow
  • Maidstone
  • Northwood
  • Oxford
  • Winchester

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

MK-3475-B49/KEYNOTE-B49: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer

Phase 3, HR+ & HER2-

More info: clinicaltrials.gov/ct2/show/NCT04895358

Recruiting now in:

  • Leicester
  • London
  • Londonderry (NI)
  • Truro

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Expanded Access for ER+ HER2- metastatic breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03763604

Recruiting now in:

  • Cambridge
  • Newcastle
  • Radlett

plasmaMATCH: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices Trial

Phase 2, metastatic or recurrent locally advanced breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03182634

Recruiting now in:

  • Bournemouth
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Exeter
  • Glasgow
  • Liverpool
  • London
  • Maidstone
  • Manchester
  • Oxford
  • Plymouth
  • Sheffield
  • Southampton
  • Sutton
  • Truro

ROLo: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Phase 2, Lobular breast cancer that is ER+/HER2- OR metastatic Triple Negative lobular breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03620643

Recruiting now in:

  • Glasgow
  • London
  • Manchester

SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer

Phase 1, advanced solid tumor ER+ & HER2-

More info: clinicaltrials.gov/ct2/show/NCT03616587

Recruiting now in:

  • Cambridge
  • Leeds
  • London
  • Manchester
  • Sutton

SERENA-4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Phase 3, ER+ & HER2-

More info: clinicaltrials.gov/ct2/show/NCT04711252

Recruiting now in:

  • Birmingham
  • Cambridge
  • Colchester
  • Leeds
  • Nottingham
  • Surrey

SERENA-6: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression

Phase 3, ER+ & HER2- & ESR1m+

More info: clinicaltrials.gov/ct2/show/NCT04964934

Recruiting now in:

  • Blackpool
  • Cambridge
  • London
  • Manchester
  • Nottingham
  • Portsmouth
  • Sheffield
  • Sutton
  • Taunton

STELLAR-001: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Phase 1, advanced solid tumor HR+ & HER2-

More info: clinicaltrials.gov/ct2/show/NCT03845166

Recruiting now in:

  • London
  • Preston
  • Sutton

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05238922

Recruiting now in:

  • London
  • Newcastle

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT04557449

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1, advanced solid tumors & PIK3CA mutant or metastatic PIK3CA-mutant HR+/HER2- breast cancer or metastatic PIK3CA-mutant HER2+ breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03006172

Recruiting now in:

  • London
  • Sutton

HER2+

For patients who are HER2 (human epidermal growth factor receptor 2) positive.

BEAMION-Lung 1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Phase 1, HER2+ solid tumour, cohort 1 is open to different types of advanced cancer, other cohorts are specific to lung cancer

More info: classic.clinicaltrials.gov/ct2/show/study/NCT04886804

Recruiting now in:

  • London
  • Sutton

CONTRAST: BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors

Phase 1 & 2, advanced solid tumor HER2+

More info: clinicaltrials.gov/ct2/show/NCT05555251

Recruiting now in:

  • Oxford

DESTINY-Breast09: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Phase 3, HER2+

More info: clinicaltrials.gov/ct2/show/NCT04784715

Recruiting now in:

  • Buckhurst Hill
  • Edinburgh
  • Guildford
  • London
  • Manchester
  • Swansea
  • Taunton

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1, Cohort 1: HER2+ Cohort 2: HER2-low

More info: clinicaltrials.gov/ct2/show/NCT04042701

Recruiting now in:

  • London
  • Manchester
  • Sutton

HER2CLIMB-05: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Phase 3, HER2+

More info: clinicaltrials.gov/ct2/show/NCT05132582

Recruiting now in:

  • Edinburgh
  • London
  • Manchester
  • Sutton

heredERA Breast Cancer: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer

Phase 3, HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT05296798

Recruiting now in:

  • Cornwall
  • London
  • Maidstone
  • Nottingham
  • Preston
  • Romford
  • Stockton-on-Tees
  • Swansea

KATE3: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic B

Phase 3, HER2+ & PD-L1+

More info: clinicaltrials.gov/ct2/show/NCT04740918

Recruiting now in:

  • London
  • Manchester
  • Nottingham

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

plasmaMATCH: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices Trial

Phase 2, metastatic or recurrent locally advanced breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03182634

Recruiting now in:

  • Bournemouth
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Exeter
  • Glasgow
  • Liverpool
  • London
  • Maidstone
  • Manchester
  • Oxford
  • Plymouth
  • Sheffield
  • Southampton
  • Sutton
  • Truro

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info: clinicaltrials.gov/ct2/show/NCT04557449

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1, advanced solid tumors & PIK3CA mutant or metastatic PIK3CA-mutant HR+/HER2- breast cancer or metastatic PIK3CA-mutant HER2+ breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03006172

Recruiting now in:

  • London
  • Sutton

HER2-

For patients who are HER2 (human epidermal growth factor receptor 2) negative.

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 & 2, advanced solid tumor HER2- & BRCA mutation

More info: clinicaltrials.gov/ct2/show/NCT04991480

Recruiting now in:

  • London

A Study of SGN-B6A in Advanced Solid Tumors

Phase 1, advanced solid tumor HER2-

More info: clinicaltrials.gov/ct2/show/NCT04389632

Recruiting now in:

  • London
  • Sutton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info: clinicaltrials.gov/ct2/show/NCT02264678

Recruiting now in:

  • Bristol
  • Cambridge
  • Coventry
  • London
  • Manchester
  • Oxford
  • Sutton
  • Withington

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

plasmaMATCH: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices Trial

Phase 2, metastatic or recurrent locally advanced breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03182634

Recruiting now in:

  • Bournemouth
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Exeter
  • Glasgow
  • Liverpool
  • London
  • Maidstone
  • Manchester
  • Oxford
  • Plymouth
  • Sheffield
  • Southampton
  • Sutton
  • Truro

TNBC

For patients who have Triple Negative Breast Cancer (TNBC) and are therefore oestrogen receptor negative, hormone receptor negative and HER2 (human epidermal growth factor receptor 2) negative.

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT04254107

Recruiting now in:

  • London
  • Sutton

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05107674

Recruiting now in:

  • Cambridge
  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Sutton

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05194072

Recruiting now in:

  • London

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT04300556

Recruiting now in:

  • London
  • Manchester

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info: clinicaltrials.gov/ct2/show/NCT04796324

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info: clinicaltrials.gov/ct2/show/NCT02264678

Recruiting now in:

  • Bristol
  • Cambridge
  • Coventry
  • London
  • Manchester
  • Oxford
  • Sutton
  • Withington

ASCENT-03: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Phase 3, metastatic untreated TNBC

More info: clinicaltrials.gov/ct2/show/NCT05382299

Recruiting now in:

  • Cheltenham
  • Glasgow
  • Leeds
  • London

ASCENT-04: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase 3, TNBC & tumors express programmed cell death ligand 1 (PD-L1).

More info: clinicaltrials.gov/ct2/show/NCT05382286

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Leeds
  • London
  • Nottingham

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Phase 1, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05082259

Recruiting now in:

  • Sutton

ATRACTIB: First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Phase 2, TNBC

More info: clinicaltrials.gov/ct2/show/NCT04408118

Recruiting now in:

  • Truro

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info: clinicaltrials.gov/ct2/show/NCT03048942

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

CURATE: TT-702 in Patients With Advanced Solid Tumours

Phase 1 & 2, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT05272709

Recruiting now in:

  • London
  • Manchester
  • Southampton

ELEVATE TNBC: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 2, TNBC

More info: clinicaltrials.gov/ct2/show/NCT04958785

Recruiting now in:

  • Leicester
  • London
  • Manchester

FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Phase 1, advanced solid tumor TNBC & FGFR2b Overexpression

More info: clinicaltrials.gov/ct2/show/NCT05325866

Recruiting now in:

  • Manchester
  • Sheffield

HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1 & 2, TNBC

More info: clinicaltrials.gov/ct2/show/NCT05057013

Recruiting now in:

  • London
  • Oxford

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

More info: clinicaltrials.gov/ct2/show/NCT03946202

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase Ib/II, TNBC

More info: classic.clinicaltrials.gov/ct2/show/NCT05714553

Recruiting now in:

  • Birmingham
  • London
  • Manchester

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Phase 1, AR+ TNBC

More info: clinicaltrials.gov/ct2/show/NCT04360941

Recruiting now in:

  • London

plasmaMATCH: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices Trial

Phase 2, metastatic or recurrent locally advanced breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03182634

Recruiting now in:

  • Bournemouth
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Exeter
  • Glasgow
  • Liverpool
  • London
  • Maidstone
  • Manchester
  • Oxford
  • Plymouth
  • Sheffield
  • Southampton
  • Sutton
  • Truro

ROLo: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Phase 2, Lobular breast cancer that is ER+/HER2- OR metastatic Triple Negative lobular breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03620643

Recruiting now in:

  • Glasgow
  • London
  • Manchester

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1 & 2, advanced solid tumor TNBC

More info: clinicaltrials.gov/ct2/show/NCT04180371

Recruiting now in:

  • Cambridge
  • Leeds
  • London
  • Manchester
  • Newcastle

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies

Phase 1 & 2, advanced solid tumor TNBC & Nectin-4 expression

More info: clinicaltrials.gov/ct2/show/NCT04561362

Recruiting now in:

  • London
  • Manchester

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info: clinicaltrials.gov/ct2/show/NCT05238922

Recruiting now in:

  • London
  • Newcastle

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumour must overexpress ANXA1

More info: www.isrctn.com/ISRCTN78740398

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

TROPION-Breast02: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy

Phase 3, TNBC & not a candidate for PD-1/PD-L1 inhibitor therapy

More info: clinicaltrials.gov/ct2/show/NCT05374512

Recruiting now in:

  • Bristol
  • Cardiff
  • Edinburgh
  • London
  • Newcastle
  • Northampton
  • Nottingham
  • Swansea
  • Warwick

Solid Tumour Studies

Studies which typically investigate many solid, late stage (i.e., advanced) cancer types within one research study, including secondary breast cancer.

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Phase 1, solid tumors of any origin

More info: clinicaltrials.gov/ct2/show/NCT05323045

Recruiting now in:

  • London

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1, Part A of study is dose escalation for advanced solid tumors

More info: clinicaltrials.gov/study/NCT05226507

Recruiting now in:

  • Sutton

A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours

Phase 2, advanced solid tumor that has come back (relapsed) or has not responded (refractory) to treatment.

More info: www.clinicaltrialsregister.eu/ctr-search/trial/2020-002428-36/GB

Recruiting now in:

  • Birmingham

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03829254

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Manchester
  • Newcastle
  • Oxford

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04969835

Recruiting now in:

  • Glasgow
  • Leeds
  • London
  • Manchester
  • Newcastle

A Study of SGN-PDL1V in Advanced Solid Tumors

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05208762

Recruiting now in:

  • London
  • Sutton

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03767075

Recruiting now in:

  • Cambridge

BEAMION-Lung 1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Phase 1, HER2+ solid tumour, cohort 1 is open to different types of advanced cancer, other cohorts are specific to lung cancer

More info: classic.clinicaltrials.gov/ct2/show/study/NCT04886804

Recruiting now in:

  • London
  • Sutton

DDRiver Solid Tumors 301: M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors

Phase 1 First in Human: Metastatic disease that is refractory to standard therapy

More info: www.clinicaltrials.gov/study/NCT04170153

Recruiting now in:

  • Cambridge
  • Manchester
  • Newcastle
  • Sutton

DETERMINE: Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial

Phase 2 & 3, "umbrella-basket platform trial" including common cancers with rare actionable genomic alterations

More info: classic.clinicaltrials.gov/ct2/show/NCT05722886

Recruiting now in:

  • Cambridge
  • Leicester
  • Manchester
  • Newcastle
  • Oxford

First in Human Study of T3P-Y058-739 (T3P)

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05120596

Recruiting now in:

  • Glasgow
  • Leeds
  • London

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1: advanced solid tumors where curative treatment options have been exhausted

More info: classic.clinicaltrials.gov/ct2/show/NCT05277051

Recruiting now in:

  • Manchester
  • Sutton

IceCAP: A Trial of Ipatasertib in Combination With Atezolizumab

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03673787

Recruiting now in:

  • Sutton

LIBRETTO-001: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Phase 1, advanced solid tumor & RET Fusion Positive

More info: clinicaltrials.gov/ct2/show/NCT03157128

Recruiting now in:

  • Sutton

LIBRETTO-121: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Phase 1 & 2, Advanced solid tumour in pediatric patients with RET gene alteration

More info: classic.clinicaltrials.gov/ct2/show/NCT03899792

Recruiting now in:

  • London

New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05117177

Recruiting now in:

  • Sutton

PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

Phase 1, metastatic solid tumour which may derive benefit from EGFR or cMet directed therapy

More info: clinicaltrials.gov/study/NCT04606381

Recruiting now in:

  • Manchester
  • Sutton

PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04644068

Recruiting now in:

  • Cambridge
  • Manchester
  • Oxford
  • Sutton

Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/study/NCT02407509

Recruiting now in:

  • London
  • Sutton

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT05471856

Recruiting now in:

  • London
  • Oxford
  • Sutton

POTENTIA: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours

Phase 1, advanced solid tumor that is PSMA+

More info: clinicaltrials.gov/ct2/show/NCT04839991

Recruiting now in:

  • London
  • Manchester
  • Sutton

PROSSPER: A study of progesterone for cancer spread to the brain

Patients with brain metastases

More info: www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-progesterone-for-cancer-spread-to-the-brain-prossper

Recruiting now in:

  • Leeds
  • Liverpool

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1, advanced solid tumor: PRAME positive tumor

More info: clinicaltrials.gov/ct2/show/NCT04262466

Recruiting now in:

  • London
  • Manchester
  • Oxford
  • Sutton

Study of ASTX029 in Subjects With Advanced Solid Tumors

Phase 1 First in Human: advanced solid malignancies who are not candidates for approved or available therapies

More info: clinicaltrials.gov/study/NCT03520075

Recruiting now in:

  • Manchester
  • Newcastle
  • Oxford

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04336241

Recruiting now in:

  • Liverpool
  • London
  • Oxford
  • Sutton

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Phase 1, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT04735978

Recruiting now in:

  • Liverpool
  • London
  • Oxford
  • Sutton

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1 & 2, advanced solid tumor

More info: clinicaltrials.gov/ct2/show/NCT03568656

Recruiting now in:

  • Belfast
  • Birmingham
  • Cambridge
  • Edinburgh
  • Glasgow
  • Leicester
  • Manchester
  • Newcastle
  • Southampton
  • Sutton

TARGET National: Tumour Characterisation to Guide Experimental Targeted Therapy

Prospective, to determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour

More info: clinicaltrials.gov/ct2/show/NCT04723316

Recruiting now in:

  • Belfast
  • Cambridge
  • Cardiff
  • Edinburgh
  • Glasgow
  • Leeds
  • Leicester
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Sheffield
  • Wirral

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumour must overexpress ANXA1

More info: www.isrctn.com/ISRCTN78740398

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1, advanced solid tumors & PIK3CA mutant or metastatic PIK3CA-mutant HR+/HER2- breast cancer or metastatic PIK3CA-mutant HER2+ breast cancer

More info: clinicaltrials.gov/ct2/show/NCT03006172

Recruiting now in:

  • London
  • Sutton

Footnotes for Healthcare Professionals

 The registry was last updated on: 4th November 2023.  

How the registry is complied

The databases used to compile this clinical trial registry are: clinicaltrials.gov, NIHR Be Part of Research and Cancer Research UK.

Only secondary breast cancer clinical trials that are noted as actively recruiting in the UK on ClinicalTrials.gov are listed in this registry. However, there can be a delay in how quickly ClinicalTrials.gov is updated and a study might be listed as actively recruiting, but has already closed to recruitment.    

There is a possibility that other clinical trials might be available due to the speed at which ClinicalTrials.gov is updated by research teams.  

Next steps

You can find out more about each specific trial by clicking its associated study link. Our Patient Trials Advocate (PTA) service is available to conduct a bespoke and detailed clinical trials search. We support patients based in the UK however we can access information on international clinical trials. Patients can self-refer to the service here.

Send feedback on the registry to: clinical.trials@make2ndscount.co.uk

Development of the registry

Make 2nds Count created the registry based on the research findings of a national survey conducted in 2021 that was funded by Make 2nds Count. The study found that secondary breast cancer patients had a lack of information about clinical trials, limited opportunities to discuss trials with their clinical team and many advocated for a patient friendly clinical trial registry specific to secondary breast cancer.

As a charity, Make 2nds Count pioneered the innovative Patient Trials Advocate (PTA) service and this dedicated UK Clinical Trials Registry to address the informational needs raised in the survey, but there is more work to be done. We all share a responsibility in igniting a national conversation about clinical trials.